{
    "PMC5564609_3": [
        {
            "subject": {
                "study": "Post-operative complications and mortalities",
                "groups": "ERAS and Conventional",
                "parameters": "various post-operative complications",
                "P-value": "P<sup>a</sup>"
            },
            "measures": "[Delayed gastric emptying, 15, 0.02]",
            "outcomes": [
                "[Bleeding, 6, 0.5]",
                "[Pancreatic fistula, 39, 0.52]",
                "[Grade A, 8, ]",
                "[Grade B, 10, ]",
                "[Grade C, 21, ]",
                "[Biliary fistula, 2, 0.47]",
                "[Wound infection, 5, 0.66]",
                "[Pulmonary complication, 2, 0.1]",
                "[Skin orifice infection, 1, 0.012]",
                "[Abdominal abscess, 0, /]",
                "[Pancreatitis, 2, 1]",
                "[Sepsis, 1, 1]",
                "[Re-laparotomy, 3, 0.6]",
                "[Mortality, 0, /]",
                "[Readmission (in 30 days), 1, 1]"
            ]
        },
        {
            "subject": {
                "study": "Post-operative complications and mortalities",
                "groups": "ERAS and Conventional",
                "parameters": "various post-operative complications",
                "P-value": "P<sup>a</sup>"
            },
            "measures": "[Delayed gastric emptying, 32, 0.02]",
            "outcomes": [
                "[Bleeding, 4, 0.5]",
                "[Pancreatic fistula, 36, 0.52]",
                "[Grade A, 6, ]",
                "[Grade B, 6, ]",
                "[Grade C, 24, ]",
                "[Biliary fistula, 0, 0.47]",
                "[Wound infection, 3, 0.66]",
                "[Pulmonary complication, 4, 0.1]",
                "[Skin orifice infection, 6, 0.012]",
                "[Abdominal abscess, 0, /]",
                "[Pancreatitis, 1, 1]",
                "[Sepsis, 0, 1]",
                "[Re-laparotomy, 1, 0.6]",
                "[Mortality, 0, /]",
                "[Readmission (in 30 days), 1, 1]"
            ]
        }
    ],
    "PMC5762325_3": [
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin Low",
                "STYK1 expression": "High",
                "correlation coefficient": "-0.420",
                "P-value": "<0.001"
            },
            "measures": "[correlation coefficient, -0.420]",
            "outcomes": "[P-value, <0.001]"
        },
        {
            "subject": {
                "analysis": "Correlation analysis between E-cadherin and STYK1 expression in pancreatic cancer",
                "tumor tissue sample": "E-cadherin High",
                "STYK1 expression": "14"
            },
            "measures": "[STYK1 expression, 34]",
            "outcomes": "[STYK1 expression, 14]"
        }
    ],
    "PMC3798558_3": [
        {
            "subject": {
                "analysis": "haplotype analysis",
                "gene": "XRCC1",
                "SNPs": "rs1799782 and rs25487",
                "R-squared": "0.15",
                "haplotype": "CA",
                "odds ratio": "1.32",
                "confidence interval": "1.01-1.71",
                "P-value": "0.042"
            },
            "measures": "[level of PC risk, statistically significant increase]",
            "outcomes": "[1.32, 0.042]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis",
                "gene": "XRCC1",
                "SNPs": "rs1799782 and rs25487",
                "haplotype": "CG",
                "odds ratio": "1.00 (ref.)",
                "confidence interval": "N/A",
                "P-value": "N/A"
            },
            "measures": "[level of PC risk, reference]",
            "outcomes": "[1.00, N/A]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis",
                "gene": "XRCC1",
                "SNPs": "rs1799782 and rs25487",
                "haplotype": "CA",
                "odds ratio": "1.05",
                "confidence interval": "0.81-1.36",
                "P-value": "0.691"
            },
            "measures": "[level of PC risk, N.E.]",
            "outcomes": "[1.05, 0.691]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis",
                "gene": "XRCC1",
                "SNPs": "rs1799782 and rs25487",
                "haplotype": "TG",
                "odds ratio": "N.E.",
                "confidence interval": "N/A",
                "P-value": "N/A"
            },
            "measures": "[level of PC risk, N.E.]",
            "outcomes": "[N.E., N/A]"
        },
        {
            "subject": {
                "analysis": "haplotype analysis",
                "gene": "XRCC1",
                "SNPs": "rs1799782 and rs25487",
                "haplotype": "TA",
                "odds ratio": "N.E.",
                "confidence interval": "N/A",
                "P-value": "N/A"
            },
            "measures": "[level of PC risk, N.E.]",
            "outcomes": "[N.E., N/A]"
        },
        {
            "subject": {
                "technique": "haplotype-effects logistic regression",
                "adjustment": "age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC"
            },
            "measures": "[N/A, N/A]",
            "outcomes": ""
        },
        {
            "subject": {
                "study population": "case-control data"
            },
            "measures": "[N/A, N/A]",
            "outcomes": ""
        },
        {
            "subject": {
                "study population": "185 cases, 1465 controls"
            },
            "measures": "[N/A, N/A]",
            "outcomes": ""
        }
    ],
    "PMC4423458_3": [
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "technique": "mass spectrometry",
                "comparison to": "controls",
                "statistical representation": "average SC and NSAF ratio",
                "replicates": "not specified"
            },
            "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
            "outcomes": [
                "[Fibrinogen beta chain isoform 1 pre-pro-protein, 70906435, 56, 138.8, 52.1, 2.2, 0.01481]",
                "[C4b-binding protein alpha chain precursor, 4502503, 67, 37.3, 11.5, 2.3, 0.04311]",
                "[Serum albumin pre-pro-protein, 4502027, 69, 986.0, 332.8, 2.4, 0.00006]",
                "[Vitamin D-binding protein isoform 1 precursor, 32483410, 53, 51.9, 19.2, 2.4, 0.03919]",
                "[Kininogen-1 isoform 2 precursor, 4504893, 48, 21.3, 5.5, 3.8, 0.01109]",
                "[Alpha-2-macroglobulin precursor, 66932947, 163, 127.9, 29.3, 3.9, 0.00618]",
                "[Haptoglobin isoform 1 pre-pro-protein, 4826762, 45, 83.8, 18.0, 4.2, 0.00024]",
                "[Fibrinogen gamma chain isoform gamma-B precursor, 70906439, 52, 89.3, 17.3, 4.3, 0.00133]",
                "[Complement C3 precursor, 115298678, 187, 174.7, 35.6, 4.3, 0.00612]",
                "[Myeloperoxidase precursor, 4557759, 84, 70.2, 11.0, 5.3, 0.02501]",
                "[Apolipoprotein A-I pre-pro-protein, 4557321, 31, 29.8, 5.9, 5.7, 0.02170]",
                "[Fibrinogen alpha chain isoform alpha-E pre-pro-protein, 4503689, 95, 63.3, 9.3, 6.4, 0.00031]",
                "[Alpha-2-HS-glycoprotein pre-pro-protein, 156523970, 39, 7.3, 1.1, 6.5, 0.00173]",
                "[Ceruloplasmin precursor, 4557485, 122, 47.3, 5.6, 7.5, 0.00114]",
                "[PREDICTED: complement C4-A isoform 1, 341916194, 193, 32.1, 4.5, 7.7, 0.01791]",
                "[Alpha-1B-glycoprotein precursor, 21071030, 54, 10.9, 1.2, 8.3, 0.00468]",
                "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]",
                "[Apolipoprotein B-100 precursor, 105990532, 516, 49.3, 1.0, 55.7, 0.02595]"
            ]
        },
        {
            "subject": {
                "analysis": "Proteins identified as more abundant in cancer (malignant strictures) than in controls (primary sclerosing cholangitis and benign strictures)",
                "technique": "mass spectrometry",
                "comparison to": "controls",
                "statistical representation": "average SC and NSAF ratio",
                "replicates": "not specified"
            },
            "measures": "[protein name, accession number, MW, average SC, NSAF ratio, P-value]",
            "outcomes": "[Inter-alpha-trypsin inhibitor heavy chain H4 isoform 1 precursor, 31542984, 103, 5.5, 0.2, 35.4, 0.00484]"
        }
    ],
    "PMC5589562_2": [
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-145-5p",
                "accession no.": "MIMAT0000437",
                "ratio": "8980.05"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-199a-5p",
                "accession no.": "MIMAT0000231",
                "ratio": "1563.68"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-199b-5p",
                "accession no.": "MIMAT0000263",
                "ratio": "296.31"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-136-5p",
                "accession no.": "MIMAT0000448",
                "ratio": "228.24"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-137",
                "accession no.": "MIMAT0000429",
                "ratio": "227.70"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-139-5p",
                "accession no.": "MIMAT0000250",
                "ratio": "216.83"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-127-3p",
                "accession no.": "MIMAT0000446",
                "ratio": "159.72"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-337-5p",
                "accession no.": "MIMAT0004695",
                "ratio": "148.57"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-139-3p",
                "accession no.": "MIMAT0004552",
                "ratio": "146.36"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-487b",
                "accession no.": "MIMAT0003180",
                "ratio": "118.72"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-199a-3p+hsa-miR-199b-3p",
                "accession no.": "MIMAT0000232",
                "ratio": "107.49"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-1233",
                "accession no.": "MIMAT0005588",
                "ratio": "66.04"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-379-5p",
                "accession no.": "MIMAT0000733",
                "ratio": "62.89"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-660-5p",
                "accession no.": "MIMAT0003338",
                "ratio": "62.50"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-335-5p",
                "accession no.": "MIMAT0000765",
                "ratio": "60.53"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-203",
                "accession no.": "MIMAT0000264",
                "ratio": "22.43"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-141-3p",
                "accession no.": "MIMAT0000432",
                "ratio": "21.69"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-96-5p",
                "accession no.": "MIMAT0000095",
                "ratio": "53.82"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-182-5p",
                "accession no.": "MIMAT0000259",
                "ratio": "55.81"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-200a-3p",
                "accession no.": "MIMAT0000682",
                "ratio": "44.88"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-4284",
                "accession no.": "MIMAT0016915",
                "ratio": "41.90"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-345-5p",
                "accession no.": "MIMAT0000772",
                "ratio": "27.99"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        },
        {
            "subject": {
                "study": "TAS cells vs. PC cells",
                "cell type": "PC cells",
                "miRNA": "hsa-miR-378g",
                "accession no.": "MIMAT0018937",
                "ratio": "25.01"
            },
            "measures": "[miRNA expression level, P]",
            "outcomes": ""
        }
    ],
    "PMC4190529_6": [
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "gemcitabine",
                "control": "5-fluorouracil",
                "phase": "3",
                "median survival": "5.7",
                "one-year survival": "4.2",
                "side effects": "more favorable than 5-fluorouracil",
                "FDA approval": "1996"
            },
            "measures": "[level of survival, P]",
            "outcomes": "[18%, 2%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "gemcitabine + erlotinib hydrochloride (Tarceva)",
                "control": "gemcitabine",
                "phase": "3",
                "median survival": "6.4",
                "one-year survival": "6",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "2005"
            },
            "measures": "[level of survival, P]",
            "outcomes": "[24%, 19%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "gemcitabine + protein-bound paclitaxel (Abraxane)",
                "control": "gemcitabine",
                "phase": "3",
                "median survival": "8.5",
                "one-year survival": "6.7",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "2013"
            },
            "measures": "[level of survival, P]",
            "outcomes": "[35%, 22%]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "FOLFIRINOX *",
                "control": "gemcitabine",
                "phase": "2/3",
                "median survival": "11.1",
                "one-year survival": "6.8",
                "side effects": "less favorable than gemcitabine",
                "FDA approval": "n/a"
            },
            "measures": "[level of survival, P]",
            "outcomes": "[48.4, 20.6]"
        },
        {
            "subject": {
                "analysis": "Summary of recent trial data for pancreatic cancer treatments",
                "treatment": "cell encapsulation + ifosfamide",
                "control": "5-fluorouracil",
                "phase": "2",
                "median survival": "10",
                "one-year survival": "5",
                "side effects": "more favorable than 5-fluorouracil or gemcitabine #",
                "FDA approval": "n/a"
            },
            "measures": "[]",
            "outcomes": ""
        }
    ],
    "PMC5675623_3": [
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "variable": "ECOG performance status",
                "contrast": "> 0 vs. 0",
                "hazard ratio": "1.47 (0.90, 2.41)",
                "P value": "0.12"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.47 (0.90, 2.41), 0.12]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "variable": "Liver metastases",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.72 (1.01, 2.91)",
                "P value": "0.045"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.72 (1.01, 2.91), 0.045]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "variable": "No. of metastatic sites",
                "contrast": ">2 vs. <= 2",
                "hazard ratio": "1.33 (0.9, 2.25)",
                "P value": "0.28"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.33 (0.9, 2.25), 0.28]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "variable": "Prior radiation therapy",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.58 (0.95, 2.61)",
                "P value": "0.077"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.58 (0.95, 2.61), 0.077]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "variable": "Prior FOLFIRINOX",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.73 (1.01, 2.98)",
                "P value": "0.046"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.73 (1.01, 2.98), 0.046]"
        },
        {
            "subject": {
                "analysis": "multivariate Cox proportional hazards regression analysis",
                "variable": "Prior gemcitabine plus nab-paclitaxel treatment",
                "contrast": "Yes vs. No",
                "hazard ratio": "1.08 (0.58, 2.01)",
                "P value": "0.80"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[1.08 (0.58, 2.01), 0.80]"
        },
        {
            "subject": {
                "study": "overall survival",
                "treatment": "first phase I treatment",
                "analysis": "multivariate Cox proportional hazards regression analysis"
            },
            "measures": "[hazard ratio, P value]",
            "outcomes": "[overall survival, first phase I treatment]"
        }
    ],
    "PMC4742219_3": [
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.874"
            },
            "measures": "[hazard ratio, 0.89]",
            "outcomes": "[0.60-1.31, 0.544]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.93",
                "confidence interval": "0.27-3.17",
                "P value": "0.906"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.54",
                "confidence interval": "1.06-2.25",
                "P value": "0.025"
            },
            "measures": "[hazard ratio, 0.99]",
            "outcomes": "[0.69-1.42, 0.967]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "2.19",
                "confidence interval": "0.87-5.49",
                "P value": "0.097"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.98-1.02, 0.883]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.25",
                "confidence interval": "0.63-2.48",
                "P value": "0.516"
            },
            "measures": "[hazard ratio, 1.91]",
            "outcomes": "[1.10-3.31, 0.022]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "6.32",
                "confidence interval": "3.12-12.79",
                "P value": "< 0.001"
            },
            "measures": "[hazard ratio, 2.09]",
            "outcomes": "[1.10-4.00, 0.025]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "2.09",
                "confidence interval": "1.10-4.00",
                "P value": "0.025"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.13",
                "confidence interval": "0.97-1.33",
                "P value": "0.127"
            },
            "measures": "[hazard ratio, 1.00]",
            "outcomes": "[0.69-1.45, 0.991]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "0.99",
                "confidence interval": "0.69-1.42",
                "P value": "0.967"
            },
            "measures": "[hazard ratio, 1.39]",
            "outcomes": "[0.81-2.38, 0.229]"
        },
        {
            "subject": {
                "analysis": "multivariable analysis",
                "variable": "Age",
                "hazard ratio": "1.00",
                "confidence interval": "0.98-1.02",
                "P value": "0.883"
            },
            "measures": "[hazard ratio, 0.93]",
            "outcomes": "[0.27-3.17, 0.906]"
        }
    ],
    "PMC4941379_3": [
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence",
                "condition": "chronic atrophic gastritis",
                "infection": "H. pylori",
                "seropositivity": "CagA",
                "sample size": "4555",
                "cases": "5",
                "crude incidence rate": "10.42",
                "HR1": "0.79 (0.15-4.08)",
                "HR2": "5.05 (1.81-14.09)"
            },
            "measures": "[HR1, HR2]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence",
                "condition": "chronic atrophic gastritis",
                "infection": "H. pylori",
                "seropositivity": "CagA",
                "sample size": "1984",
                "cases": "2",
                "crude incidence rate": "9.54",
                "HR1": "0.79 (0.15-4.08)",
                "HR2": "5.05 (1.81-14.09)"
            },
            "measures": "[HR1, HR2]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence",
                "condition": "chronic atrophic gastritis",
                "infection": "H. pylori",
                "seropositivity": "CagA",
                "sample size": "2295",
                "cases": "14",
                "crude incidence rate": "58.13",
                "HR1": "5.05 (1.81-14.09)",
                "HR2": "12.51 (3.57-43.22)"
            },
            "measures": "[HR1, HR2]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence",
                "condition": "chronic atrophic gastritis",
                "infection": "H. pylori",
                "seropositivity": "CagA",
                "sample size": "205",
                "cases": "0",
                "crude incidence rate": "0",
                "HR1": "3.45 (1.38-8.64)",
                "HR2": "Not estimable"
            },
            "measures": "[HR1]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence",
                "condition": "chronic atrophic gastritis",
                "infection": "H. pylori",
                "seropositivity": "CagA",
                "sample size": "143",
                "cases": "1",
                "crude incidence rate": "64.61",
                "HR1": "5.50 (0.63-47.57)",
                "HR2": "Not estimable"
            },
            "measures": "[HR1]",
            "outcomes": ""
        },
        {
            "subject": {
                "analysis": "Risk of gastric cancer incidence",
                "condition": "chronic atrophic gastritis",
                "infection": "H. pylori",
                "seropositivity": "CagA",
                "sample size": "315",
                "cases": "5",
                "crude incidence rate": "151.20",
                "HR1": "12.51 (3.57-43.22)",
                "HR2": "Not estimable"
            },
            "measures": "[HR1]",
            "outcomes": ""
        }
    ],
    "PMC3987090_4": [
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[12.8 (9.4\u201316.2), 1, 0.86\u20133.29, 0.13]",
                "[11.7 (10.4\u201313.0), 1.68, , 0.37]",
                "[14.8 (11.5\u201318.2), 1, 1.13\u20132.05, 0.01]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        },
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[14.8 (11.5\u201318.2), 1, 1.13\u20132.05, 0.01]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        },
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[12.8 (9.4\u201316.2), 1, 0.86\u20133.29, 0.13]",
                "[11.7 (10.4\u201313.0), 1.68, , 0.37]",
                "[14.8 (11.5\u201318.2), 1, 1.13\u20132.05, 0.01]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        },
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[11.7 (10.4\u201313.0), 1.68, , 0.37]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        },
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[12.8 (9.4\u201316.2), 1, 0.86\u20133.29, 0.13]",
                "[11.7 (10.4\u201313.0), 1.68, , 0.37]",
                "[14.8 (11.5\u201318.2), 1, 1.13\u20132.05, 0.01]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        },
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[14.8 (11.5\u201318.2), 1, 1.13\u20132.05, 0.01]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        },
        {
            "subject": {
                "analysis": "NLR thresholds and relationship with survival",
                "threshold": ">5",
                "statistical representation": "P-value"
            },
            "measures": "[median OS (95% CI) (months), hazard ratio, 95% CI, P-value]",
            "outcomes": [
                "[12.8 (9.4\u201316.2), 1, 0.86\u20133.29, 0.13]",
                "[11.7 (10.4\u201313.0), 1.68, , 0.37]",
                "[14.8 (11.5\u201318.2), 1, 1.13\u20132.05, 0.01]",
                "[10.7 (9.3\u201312.1), 1.52, , 0.24]",
                "[13.4 (11.1\u201315.7), 1, 1.26\u20132.23, <0.01]",
                "[8.6 (6.2\u201311.0), 1.68, , <0.01]",
                "[13.3 (11.4\u201315.2), 1, 1.44\u20132.78, <0.01]",
                "[7.3 (5.6\u20139.0), 2.00, , <0.01]",
                "[12.8 (10.7\u201314.9), 1, 1.50\u20133.15, <0.01]",
                "[6.0 (2.8\u20139.2), 2.17, , <0.01]"
            ]
        }
    ],
    "PMC3987090_5": [
        {
            "subject": {
                "study": "An X et al",
                "year": "2010",
                "n": "89",
                "NLR >5": "17.9%",
                "OS (NLR >5 vs <=5)": "2.4 vs 7.7",
                "HR": "4.49",
                "P": "0.013"
            },
            "measures": "[NLR, OS]",
            "outcomes": "[17.9%, 2.4 vs 7.7]"
        },
        {
            "subject": {
                "study": "Wang DS et al",
                "year": "2012",
                "n": "86",
                "NLR >5": "13.9%",
                "OS (NLR >5 vs <=5)": "5.8 vs 10.2",
                "HR": "NA",
                "P": "NA"
            },
            "measures": "[NLR, OS]",
            "outcomes": "[13.9%, 5.8 vs 10.2]"
        },
        {
            "subject": {
                "study": "Stotz M et al",
                "year": "2013",
                "n": "261",
                "NLR >5": "30.3%",
                "OS (NLR >5 vs <=5)": "NA",
                "HR": "2.53",
                "P": "< 0.01"
            },
            "measures": "[NLR, OS]",
            "outcomes": "[30.3%, NA]"
        },
        {
            "subject": {
                "study": "Our study",
                "year": "2013",
                "n": "253",
                "NLR >5": "15.8%",
                "OS (NLR >5 vs <=5)": "6.0 vs 12.8",
                "HR": "1.95",
                "P": "< 0.01"
            },
            "measures": "[NLR, OS]",
            "outcomes": "[15.8%, 6.0 vs 12.8]"
        },
        {
            "subject": {
                "analysis": "Summary of published studies reporting the association between NLR and the prognosis of APC patients receiving chemotherapy",
                "prognostic factor": "NLR",
                "study design": "published studies",
                "patient population": "APC patients receiving chemotherapy"
            },
            "measures": "[NLR, OS]",
            "outcomes": "[]"
        }
    ],
    "PMC3544459_4": [
        {
            "subject": {
                "condition": "Yes",
                "median survival time": "33.2 \u00b1 1.8",
                "P value": "0.049",
                "HR (95% CI)": "1.0"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.050]"
        },
        {
            "subject": {
                "condition": "Yes",
                "median survival time": "24.6 \u00b1 2.5",
                "HR (95% CI)": "1.27 (1.00\u20131.60)"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.005]"
        },
        {
            "subject": {
                "condition": "Yes",
                "median survival time": "51.7 \u00b1 31.1",
                "P value": "<0.001",
                "HR (95% CI)": "1.0"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[<0.001]"
        },
        {
            "subject": {
                "condition": "Yes",
                "median survival time": "29.4 \u00b1 1.64",
                "HR (95% CI)": "2.01 (1.38\u20132.93)"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.019]"
        },
        {
            "subject": {
                "condition": "Positive",
                "median survival time": "33.6 \u00b1 1.7",
                "P value": "<0.001",
                "HR (95% CI)": "1.0"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.003]"
        },
        {
            "subject": {
                "condition": "Positive",
                "median survival time": "24.8 \u00b1 2.6",
                "HR (95% CI)": "1.62 (1.27\u20132.08)"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.003]"
        },
        {
            "subject": {
                "condition": "Positive",
                "median survival time": "38.6 \u00b1 5.3",
                "P value": "<0.001",
                "HR (95% CI)": "1.0"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.002]"
        },
        {
            "subject": {
                "condition": "Positive",
                "median survival time": "27.5 \u00b1 1.3",
                "HR (95% CI)": "1.70 (1.35\u20132.15)"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[0.002]"
        },
        {
            "subject": {
                "condition": "Poor",
                "median survival time": "35.9 \u00b1 2.68",
                "P value": "<0.001",
                "HR (95% CI)": "1.0"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[<0.001]"
        },
        {
            "subject": {
                "condition": "Poor",
                "median survival time": "26.0 \u00b1 1.77",
                "HR (95% CI)": "1.63 (1.32\u20132.02)"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[<0.001]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "technique": "log-rank",
                "statistical representation": "median survival time \u00b1 SD",
                "replicates": "N/A"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[N/A]"
        },
        {
            "subject": {
                "analysis": "Overall survival and risk of death by clinical characteristics",
                "technique": "log-rank",
                "statistical representation": "HR (95% CI)",
                "replicates": "N/A"
            },
            "measures": "[level of risk, P]",
            "outcomes": "[N/A]"
        }
    ],
    "PMC3497287_3": [
        {
            "subject": {
                "syndrome": "Lynch Syndrome",
                "gene": "MMR: MLH1, MSH2, MSH6 and PMS2"
            },
            "measures": "[mutated gene, MMR: MLH1, MSH2, MSH6 and PMS2]",
            "outcomes": ""
        },
        {
            "subject": {
                "syndrome": "Peutz-Jeghers Syndrome",
                "gene": "STK11/LKB1"
            },
            "measures": "[mutated gene, STK11/LKB1]",
            "outcomes": ""
        },
        {
            "subject": {
                "syndrome": "Hereditary Breast Cancer",
                "gene": "BRCA1/BRCA2"
            },
            "measures": "[mutated gene, BRCA1/BRCA2]",
            "outcomes": ""
        },
        {
            "subject": {
                "syndrome": "Familial Atypical Multiple Mole Melanoma",
                "gene": "CDKN2A mutation"
            },
            "measures": "[mutated gene, CDKN2A mutation]",
            "outcomes": ""
        }
    ],
    "PMC4728116_3": [
        {
            "subject": {
                "study": "pancreatic cancer",
                "characteristics": "risk factors",
                "technique": "case-control study",
                "population": "patients",
                "outcome": "odds ratio"
            },
            "measures": "[family history of pancreatic cancer, 3.67 (1.02\u201313.14)]",
            "outcomes": [
                "[family history of pancreatic cancer, 4.04 (1.08\u201315.07)]",
                "[family history of pancreatic cancer, 1.23 (1.11\u20133.70)]"
            ]
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "characteristics": "risk factors",
                "technique": "case-control study",
                "population": "patients",
                "outcome": "odds ratio"
            },
            "measures": "[BMI, 1.67 (1.18\u20132.38)]",
            "outcomes": [
                "[BMI, 1.78 (1.23\u20132.58)]",
                "[BMI, 1.77 (1.22\u20132.57)]"
            ]
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "characteristics": "risk factors",
                "technique": "case-control study",
                "population": "patients",
                "outcome": "odds ratio"
            },
            "measures": "[diabetes, 2.69 (1.51\u20134.77)]",
            "outcomes": [
                "[diabetes, 2.60 (1.41\u20134.79)]",
                "[diabetes, 2.96 (1.48\u20135.92)]"
            ]
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "characteristics": "risk factors",
                "technique": "case-control study",
                "population": "patients",
                "outcome": "odds ratio"
            },
            "measures": "[cholecystitis, 1.89 (0.84\u20134.24)]",
            "outcomes": [
                "[cholecystitis, 1.91 (0.83\u20134.38)]",
                "[cholecystitis, 1.35 (0.50\u20133.68)]"
            ]
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "characteristics": "risk factors",
                "technique": "case-control study",
                "population": "patients",
                "outcome": "odds ratio"
            },
            "measures": "[gallstone, 2.80 (1.01\u20137.77)]",
            "outcomes": [
                "[gallstone, 2.58 (0.89\u20137.44)]",
                "[gallstone, 2.68 (0.65\u201311.07)]"
            ]
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "characteristics": "risk factors",
                "technique": "case-control study",
                "population": "patients",
                "outcome": "odds ratio",
                "OR": "odds ratio",
                "adjusted for": "age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables"
            },
            "measures": "[CI, 95% confidence interval|, |OR, odds ratio|, |adjusted for, age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, BMI, diabetes, gallstone, pickles and vegetables|]",
            "outcomes": ""
        }
    ],
    "PMC4741511_2": [
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "LDH serum levels": "\u2264 UNR",
                "sorafenib": "yes",
                "no sorafenib": "no",
                "PFS": "7.6 months",
                "OS": "12.7 months"
            },
            "measures": "[PFS, 0.05]",
            "outcomes": "[OS, 0.0012]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "LDH serum levels": "> UNR",
                "sorafenib": "yes",
                "no sorafenib": "no"
            },
            "measures": "[PFS, 2.8 months]",
            "outcomes": "[OS, 5.9 months]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "LDH serum levels": "\u2264 UNR",
                "sorafenib": "no",
                "no sorafenib": "yes"
            },
            "measures": "[PFS, 3.3 months]",
            "outcomes": "[OS, 8.6 months]"
        },
        {
            "subject": {
                "study": "MAPS phase II",
                "population": "study population",
                "stratification": "LDH serum levels and treatment",
                "treatment": "chemotherapy plus sorafenib or chemotherapy alone",
                "LDH serum levels": "> UNR",
                "sorafenib": "no",
                "no sorafenib": "yes"
            },
            "measures": "[PFS, 2.2 months]",
            "outcomes": "[OS, 5.2 months]"
        }
    ],
    "PMC5522086_3": [
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "technique": "statistical analysis",
                "statistical parameter": "Activation z-score",
                "threshold": "z<0",
                "comparison to": "random predictions"
            },
            "measures": "[z-score, P-value]",
            "outcomes": [
                "[\u22122.353, 3.34\u00d710^\u221232]",
                "[\u22123.977, 4.62\u00d710^\u221213]",
                "[\u22123.455, 5.88\u00d710^\u221212]",
                "[\u22122.359, 8.82\u00d710^\u221212]",
                "[\u22123.219, 1.34\u00d710^\u221211]",
                "[\u22122.299, 9.57\u00d710^\u221210]",
                "[\u22124.286, 3.74\u00d710^\u221208]",
                "[\u22123.116, 4.32\u00d710^\u221208]",
                "[\u22123.714, 6.26\u00d710^\u221207]",
                "[\u22122.313, 1.60\u00d710^\u221206]",
                "[\u22122.876, 7.26\u00d710^\u221206]",
                "[\u22122.7, 1.09\u00d710^\u221205]",
                "[\u22122.41, 4.24\u00d710^\u221205]",
                "[\u22123.124, 1.72\u00d710^\u221204]",
                "[\u22122.887, 2.39\u00d710^\u221204]",
                "[2.924, 5.78\u00d710^\u221219]",
                "[3.359, 1.99\u00d710^\u221215]",
                "[2.06, 4.79\u00d710^\u221213]",
                "[2.866, 2.62\u00d710^\u221212]",
                "[6.314, 1.43\u00d710^\u221211]",
                "[4.99, 1.62\u00d710^\u221211]",
                "[3.759, 2.76\u00d710^\u221211]",
                "[5.591, 2.88\u00d710^\u221210]",
                "[4.395, 5.12\u00d710^\u221210]",
                "[4.576, 2.05\u00d710^\u221208]",
                "[2.575, 5.06\u00d710^\u221208]",
                "[2.045, 5.57\u00d710^\u221208]",
                "[3.242, 9.35\u00d710^\u221208]",
                "[2.394, 1.16\u00d710^\u221206]",
                "[2.549, 5.41\u00d710^\u221206]"
            ]
        },
        {
            "subject": {
                "analysis": "Top 15 significant upstream transcription regulators",
                "technique": "statistical analysis",
                "statistical parameter": "Overlap P-value",
                "threshold": "P < 0.01",
                "comparison to": "random predictions"
            },
            "measures": "[P-value]",
            "outcomes": [
                "[3.34\u00d710^\u221232]",
                "[4.62\u00d710^\u221213]",
                "[5.88\u00d710^\u221212]",
                "[8.82\u00d710^\u221212]",
                "[1.34\u00d710^\u221211]",
                "[9.57\u00d710^\u221210]",
                "[3.74\u00d710^\u221208]",
                "[4.32\u00d710^\u221208]",
                "[6.26\u00d710^\u221207]",
                "[1.60\u00d710^\u221206]",
                "[7.26\u00d710^\u221206]",
                "[1.09\u00d710^\u221205]",
                "[4.24\u00d710^\u221205]",
                "[1.72\u00d710^\u221204]",
                "[2.39\u00d710^\u221204]",
                "[5.78\u00d710^\u221219]",
                "[1.99\u00d710^\u221215]",
                "[4.79\u00d710^\u221213]",
                "[2.62\u00d710^\u221212]",
                "[1.43\u00d710^\u221211]",
                "[1.62\u00d710^\u221211]",
                "[2.76\u00d710^\u221211]",
                "[2.88\u00d710^\u221210]",
                "[5.12\u00d710^\u221210]",
                "[2.05\u00d710^\u221208]",
                "[5.06\u00d710^\u221208]",
                "[5.57\u00d710^\u221208]",
                "[9.35\u00d710^\u221208]",
                "[1.16\u00d710^\u221206]",
                "[5.41\u00d710^\u221206]"
            ]
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "TP53",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.977",
                "overlap P-value": "4.62\u00d710^\u221213"
            },
            "measures": "[\u22122.52, \u22123.977, 4.62\u00d710^\u221213]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "NUPR1",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.977",
                "overlap P-value": "4.62\u00d710^\u221213"
            },
            "measures": "[\u22122.52, \u22123.977, 4.62\u00d710^\u221213]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "NKX2-3",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.455",
                "overlap P-value": "5.88\u00d710^\u221212"
            },
            "measures": "[\u22122.52, \u22123.455, 5.88\u00d710^\u221212]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "HNF1A",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22122.359",
                "overlap P-value": "8.82\u00d710^\u221212"
            },
            "measures": "[\u22122.52, \u22122.359, 8.82\u00d710^\u221212]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "CDKN2A",
                "log ratio": "1.737",
                "activation z-score": "\u22123.219",
                "overlap P-value": "1.34\u00d710^\u221211"
            },
            "measures": "[1.737, \u22123.219, 1.34\u00d710^\u221211]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "estrogen receptor",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22122.299",
                "overlap P-value": "9.57\u00d710^\u221210"
            },
            "measures": "[\u22122.52, \u22122.299, 9.57\u00d710^\u221210]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "RB1",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22124.286",
                "overlap P-value": "3.74\u00d710^\u221208"
            },
            "measures": "[\u22122.52, \u22124.286, 3.74\u00d710^\u221208]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "TCF3",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.116",
                "overlap P-value": "4.32\u00d710^\u221208"
            },
            "measures": "[\u22122.52, \u22123.116, 4.32\u00d710^\u221208]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "TRIM24",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.714",
                "overlap P-value": "6.26\u00d710^\u221207"
            },
            "measures": "[\u22122.52, \u22123.714, 6.26\u00d710^\u221207]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "BCL6",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22122.313",
                "overlap P-value": "1.60\u00d710^\u221206"
            },
            "measures": "[\u22122.52, \u22122.313, 1.60\u00d710^\u221206]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "NR5A2",
                "log ratio": "\u22122.876",
                "activation z-score": "\u22122.7",
                "overlap P-value": "7.26\u00d710^\u221206"
            },
            "measures": "[\u22122.876, \u22122.7, 7.26\u00d710^\u221206]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "SATB1",
                "log ratio": "\u22120.814",
                "activation z-score": "\u22122.003",
                "overlap P-value": "1.09\u00d710^\u221205"
            },
            "measures": "[\u22120.814, \u22122.003, 1.09\u00d710^\u221205]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "IRF4",
                "log ratio": "2.115",
                "activation z-score": "\u22122.41",
                "overlap P-value": "4.24\u00d710^\u221205"
            },
            "measures": "[2.115, \u22122.41, 4.24\u00d710^\u221205]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "RBL1",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22123.124",
                "overlap P-value": "1.72\u00d710^\u221204"
            },
            "measures": "[\u22122.52, \u22123.124, 1.72\u00d710^\u221204]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Inhibition",
                "upstream regulator": "SPDEF",
                "log ratio": "\u22122.52",
                "activation z-score": "\u22122.887",
                "overlap P-value": "2.39\u00d710^\u221204"
            },
            "measures": "[\u22122.52, \u22122.887, 2.39\u00d710^\u221204]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "STAT3",
                "log ratio": "\u22122.52",
                "activation z-score": "2.924",
                "overlap P-value": "5.78\u00d710^\u221219"
            },
            "measures": "[\u22122.52, 2.924, 5.78\u00d710^\u221219]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "CTNNB1",
                "log ratio": "\u22122.52",
                "activation z-score": "3.359",
                "overlap P-value": "1.99\u00d710^\u221215"
            },
            "measures": "[\u22122.52, 3.359, 1.99\u00d710^\u221215]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "SP1",
                "log ratio": "\u22122.52",
                "activation z-score": "2.06",
                "overlap P-value": "4.79\u00d710^\u221213"
            },
            "measures": "[\u22122.52, 2.06, 4.79\u00d710^\u221213]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "CEBPB",
                "log ratio": "\u22122.52",
                "activation z-score": "2.866",
                "overlap P-value": "2.62\u00d710^\u221212"
            },
            "measures": "[\u22122.52, 2.866, 2.62\u00d710^\u221212]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "NFkB (complex)",
                "log ratio": "\u22122.52",
                "activation z-score": "6.314",
                "overlap P-value": "1.43\u00d710^\u221211"
            },
            "measures": "[\u22122.52, 6.314, 1.43\u00d710^\u221211]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "TBX2",
                "log ratio": "\u22122.52",
                "activation z-score": "4.99",
                "overlap P-value": "1.62\u00d710^\u221211"
            },
            "measures": "[\u22122.52, 4.99, 1.62\u00d710^\u221211]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "IRF1",
                "log ratio": "\u22122.52",
                "activation z-score": "3.759",
                "overlap P-value": "2.76\u00d710^\u221211"
            },
            "measures": "[\u22122.52, 3.759, 2.76\u00d710^\u221211]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "IRF7",
                "log ratio": "1.504",
                "activation z-score": "5.591",
                "overlap P-value": "2.88\u00d710^\u221210"
            },
            "measures": "[1.504, 5.591, 2.88\u00d710^\u221210]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "FOXM1",
                "log ratio": "2.152",
                "activation z-score": "4.395",
                "overlap P-value": "5.12\u00d710^\u221210"
            },
            "measures": "[2.152, 4.395, 5.12\u00d710^\u221210]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "STAT1",
                "log ratio": "\u22122.52",
                "activation z-score": "4.576",
                "overlap P-value": "2.05\u00d710^\u221208"
            },
            "measures": "[\u22122.52, 4.576, 2.05\u00d710^\u221208]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "ETS1",
                "log ratio": "0.863",
                "activation z-score": "2.575",
                "overlap P-value": "5.06\u00d710^\u221208"
            },
            "measures": "[0.863, 2.575, 5.06\u00d710^\u221208]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "JUN",
                "log ratio": "\u22122.52",
                "activation z-score": "2.045",
                "overlap P-value": "5.57\u00d710^\u221208"
            },
            "measures": "[\u22122.52, 2.045, 5.57\u00d710^\u221208]",
            "outcomes": ""
        },
        {
            "subject": {
                "group": "Activation",
                "upstream regulator": "FOXO1",
                "log ratio": "\u22122.52",
                "activation z-score": "3.242",
                "overlap P-value": "9.35\u00d710^\u221208"
            },
            "measures": "[\u22122.52, 3.242, 9.35\u00d710^\u221208]",
            "outcomes": ""
        }
    ],
    "PMC3428781_1": [
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "vitamin A lipid droplets",
                "state": "absent"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "\u03b1 Smooth muscle actin",
                "state": "present"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "proliferation",
                "state": "increased"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "migration",
                "state": "increased"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "extracellular matrix production",
                "state": "increased"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "matrix metalloproteinases (MMPs) and tissue inhibitors of matrix proteinases (TIMPs)",
                "state": "change in types of MMPs and TIMPs to facilitate ECM deposition"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "production of cytokines",
                "state": "increased (PDGF, TGF\u03b2, CTGF, IL1, IL6, IL15)"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "capacity for phagocytosis",
                "state": "present"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        },
        {
            "subject": {
                "phenotype": "activated PSCs",
                "characteristic": "proteomic analyses",
                "state": "differential expression of proteins related to the cell cytoskeleton, cell metabolism, motility, growth and invasion"
            },
            "measures": "[characteristics of quiescent and activated PSCs, none]",
            "outcomes": "[none]"
        }
    ],
    "PMC4941331_3": [
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "CDH1 expression": "cytoplasmic",
                "HDAC3 expression": "nuclear",
                "correlation coefficient": "Spearman",
                "P-value": "0.001"
            },
            "measures": "[correlation coefficient, 0.440]",
            "outcomes": "[P-value, < 0.001]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "CDH1 expression": "cytoplasmic",
                "HDAC3 expression": "nuclear",
                "correlation coefficient": "Spearman",
                "P-value": "0.001"
            },
            "measures": "[correlation coefficient, -0.348]",
            "outcomes": "[P-value, 0.001]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "CDH1 expression": "cytoplasmic",
                "HDAC3 expression": "nuclear",
                "correlation coefficient": "Spearman",
                "P-value": "> 0.05"
            },
            "measures": "[correlation coefficient, -]",
            "outcomes": "[P-value, > 0.05]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "CDH1 expression": "cytoplasmic",
                "HDAC3 expression": "nuclear",
                "correlation coefficient": "Spearman",
                "P-value": "> 0.05"
            },
            "measures": "[correlation coefficient, -]",
            "outcomes": "[P-value, > 0.05]"
        },
        {
            "subject": {
                "analysis": "Association between nuclear HDAC3 and cytoplasmic CDH1 expression",
                "CDH1 expression": "cytoplasmic",
                "HDAC3 expression": "nuclear",
                "correlation coefficient": "Spearman",
                "P-value": "> 0.05"
            },
            "measures": "[correlation coefficient, -]",
            "outcomes": "[P-value, > 0.05]"
        }
    ],
    "PMC6062623_3": [
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density": "0.1",
                "statistical representation": "t-statistic",
                "p-value": "0.002"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.76, 0.002]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density": "0.15",
                "statistical representation": "t-statistic",
                "p-value": "0.008"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.15, 0.008]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density": "0.2",
                "statistical representation": "t-statistic",
                "p-value": "0.006"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.25, 0.006]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Right",
                "density": "0.25",
                "statistical representation": "t-statistic",
                "p-value": "0.009"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.08, 0.009]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density": "0.1",
                "statistical representation": "t-statistic",
                "p-value": "0.32"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-1.04, 0.32]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density": "0.15",
                "statistical representation": "t-statistic",
                "p-value": "0.022"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-2.58, 0.022]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density": "0.2",
                "statistical representation": "t-statistic",
                "p-value": "0.005"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.36, 0.005]"
        },
        {
            "subject": {
                "hypothesis": "State transition",
                "graph metric": "Local efficiency",
                "hemisphere": "Left",
                "density": "0.25",
                "statistical representation": "t-statistic",
                "p-value": "0.01"
            },
            "measures": "[t-statistic, p-value]",
            "outcomes": "[-3.04, 0.01]"
        }
    ],
    "PMC5464866_2": [
        {
            "subject": {
                "study": "pancreatic cancer",
                "method": "immunohistochemistry",
                "protein": "FXR",
                "expression": "different levels",
                "tissues": "cancerous and adjacent",
                "statistical significance": "p < 0.05"
            },
            "measures": "[FXR expression in cancerous tissues, FXR expression in adjacent tissues]",
            "outcomes": "[88, 88]"
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "method": "immunohistochemistry",
                "protein": "FXR",
                "expression": "different levels",
                "tissues": "cancerous and adjacent",
                "statistical significance": "p < 0.05"
            },
            "measures": "[positive FXR expression in cancerous tissues, positive FXR expression in adjacent tissues]",
            "outcomes": "[54, 27]"
        },
        {
            "subject": {
                "study": "pancreatic cancer",
                "method": "immunohistochemistry",
                "protein": "FXR",
                "expression": "different levels",
                "tissues": "cancerous and adjacent",
                "statistical significance": "p < 0.05"
            },
            "measures": "[negative FXR expression in cancerous tissues, negative FXR expression in adjacent tissues]",
            "outcomes": "[34, 61]"
        }
    ],
    "PMC5687650_6": [
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Gender",
                "category": "Women or Men",
                "OR (95% CI)": "0.770 (0.528-1.124)",
                "P value": "0.175"
            },
            "measures": "[statistical significance, -]",
            "outcomes": "[overall survival, -]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Age",
                "category": ">65 years or \u226465 years",
                "OR (95% CI)": "0.773 (0.537-1.110)",
                "P value": "0.163"
            },
            "measures": "[statistical significance, -]",
            "outcomes": "[overall survival, -]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "PLR",
                "category": "high or low",
                "OR (95% CI)": "0.922 (0.641-1.325)",
                "P value": "0.660"
            },
            "measures": "[statistical significance, -]",
            "outcomes": "[overall survival, -]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "NLR",
                "category": "high or low",
                "OR (95% CI)": "1.007 (0.701-1.448)",
                "P value": "0.969"
            },
            "measures": "[statistical significance, -]",
            "outcomes": "[overall survival, -]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy PLR ratio",
                "category": ">1 or \u22641",
                "OR (95% CI)": "1.272 (0.881-1.837)",
                "P value": "0.199"
            },
            "measures": "[statistical significance, -]",
            "outcomes": "[overall survival, -]"
        },
        {
            "subject": {
                "analysis": "Univariate and multivariate analysis of risk factors for the overall survival",
                "risk factor": "Post/pre-chemotherapy NLR ratio",
                "category": ">1 or \u22641",
                "OR (95% CI)": "1.902 (1.290-2.803)",
                "P value": "0.001**"
            },
            "measures": "[statistical significance, **]",
            "outcomes": "[overall survival, -]"
        }
    ],
    "PMC5464866_1": [
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "0 year",
                "group": "Low",
                "number at risk": "87 (49.7%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.83]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "2 year",
                "group": "Low",
                "number at risk": "16 (9.1%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.83]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "4 year",
                "group": "Low",
                "number at risk": "6 (3.4%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.83]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "6 year",
                "group": "Low",
                "number at risk": "1 (0.6%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.83]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "0 year",
                "group": "High",
                "number at risk": "88 (50.3%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.78]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "2 year",
                "group": "High",
                "number at risk": "9 (5.1%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.78]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "4 year",
                "group": "High",
                "number at risk": "3 (1.7%)"
            },
            "measures": "[median survival time, year]",
            "outcomes": "[1.78]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "6 year",
                "group": "High",
                "number at risk": "0 (0.0%)"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.4288 (0.3020~0.6089)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "0 year",
                "group": "Low"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.4288 (0.3020~0.6089)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "2 year",
                "group": "Low"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.4288 (0.3020~0.6089)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "4 year",
                "group": "Low"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.4288 (0.3020~0.6089)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "6 year",
                "group": "Low"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.3127 (0.1776~0.5503)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "0 year",
                "group": "High"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.3036 (0.1646~0.5600)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "2 year",
                "group": "High"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.3036 (0.1646~0.5600)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "4 year",
                "group": "High"
            },
            "measures": "[three year survival rate, 95% CI]",
            "outcomes": "[0.3036 (0.1646~0.5600)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "6 year",
                "group": "High"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.2277 (0.0989~0.5241)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "0 year",
                "group": "Low"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.3127 (0.1776~0.5503)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "2 year",
                "group": "Low"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.3127 (0.1776~0.5503)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "4 year",
                "group": "Low"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.3127 (0.1776~0.5503)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "6 year",
                "group": "Low"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.3127 (0.1776~0.5503)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "0 year",
                "group": "High"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.2277 (0.0989~0.5241)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "2 year",
                "group": "High"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.2277 (0.0989~0.5241)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "4 year",
                "group": "High"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.2277 (0.0989~0.5241)]"
        },
        {
            "subject": {
                "analysis": "survival analysis",
                "cancer type": "pancreatic cancer",
                "expression": "FXR",
                "time point": "6 year",
                "group": "High"
            },
            "measures": "[five year survival rate]",
            "outcomes": "[0.2277 (0.0989~0.5241)]"
        }
    ],
    "PMC5641200_3": [
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Red blood cells count decreased",
                "n": "5",
                "percentage": "83",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Leukopenia",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Neutropenia",
                "n": "4",
                "percentage": "67",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "AST increase",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "ALT increase",
                "n": "4",
                "percentage": "67",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "GGT increase",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Hypocalcemia",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Hyponatremia",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Nausea",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Vomiting",
                "n": "2",
                "percentage": "33",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Diarrhea",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Abdominal pain",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Oral mucositis",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Dyspepsia",
                "n": "2",
                "percentage": "33",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Dysgeusia",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Anorexia",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Alopecia",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Fatigue",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Pneumonitis",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Peripheral sensory neuropathy",
                "n": "3",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Arthralgia",
                "n": "2",
                "percentage": "33",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Myalgia",
                "n": "1",
                "percentage": "17",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "LVEF decrease",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 1",
                "AE": "Pericardial effusion",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Red blood cells count decreased",
                "n": "2",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Leukopenia",
                "n": "2",
                "percentage": "50",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Neutropenia",
                "n": "1",
                "percentage": "25",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "AST increase",
                "n": "4",
                "percentage": "100",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "ALT increase",
                "n": "3",
                "percentage": "75",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "GGT increase",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Hypocalcemia",
                "n": "1",
                "percentage": "25",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Hyponatremia",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Nausea",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Vomiting",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Diarrhea",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Abdominal pain",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Oral mucositis",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Dyspepsia",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Dysgeusia",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Anorexia",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Alopecia",
                "n": "1",
                "percentage": "25",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Fatigue",
                "n": "3",
                "percentage": "75",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Pneumonitis",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Peripheral sensory neuropathy",
                "n": "1",
                "percentage": "25",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Arthralgia",
                "n": "1",
                "percentage": "25",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Myalgia",
                "n": "-",
                "percentage": "-",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "LVEF decrease",
                "n": "1",
                "percentage": "25",
                "comparison to": "-"
            },
            "measures": "[statistical representation, -]",
            "outcomes": "[outcome, -]"
        },
        {
            "subject": {
                "analysis": "Treatment related adverse events by dose level",
                "dose level": "Level 2",
                "AE": "Pericardial effusion",
                "n": "-"
            }
        }
    ],
    "PMC5716794_2": [
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "55",
                "optimal cutoff value": "1.70",
                "AUC": "0.687 \u00b1 0.079 (0.575\u22120.785)",
                "sensitivity": "89.1 (78.8 \u221295.5)",
                "specificity": "50.0 (26.0 \u221274.0)",
                "PPV": "86.4",
                "NPV": "56.3",
                "ACC": "80.5"
            },
            "measures": "[level of accuracy, 0.687 \u00b1 0.079 (0.575\u22120.785)]",
            "outcomes": "[0.687 \u00b1 0.079 (0.575\u22120.785)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "82",
                "optimal cutoff value": "1.72",
                "AUC": "0.694 \u00b1 0.077 (0.582\u22120.791)",
                "sensitivity": "90.6 (80.7 \u221296.5)",
                "specificity": "50.0 (26.0 \u221274.0)",
                "PPV": "86.6",
                "NPV": "59.9",
                "ACC": "81.7"
            },
            "measures": "[level of accuracy, 0.694 \u00b1 0.077 (0.582\u22120.791)]",
            "outcomes": "[0.694 \u00b1 0.077 (0.582\u22120.791)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "99",
                "optimal cutoff value": "1.73",
                "AUC": "0.707 \u00b1 0.074 (0.596\u22120.802)",
                "sensitivity": "90.6 (80.7 \u221296.5)",
                "specificity": "50.0 (26.0 \u221274.0)",
                "PPV": "86.6",
                "NPV": "59.9",
                "ACC": "81.7"
            },
            "measures": "[level of accuracy, 0.707 \u00b1 0.074 (0.596\u22120.802)]",
            "outcomes": "[0.707 \u00b1 0.074 (0.596\u22120.802)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "134",
                "optimal cutoff value": "1.74",
                "AUC": "0.731 \u00b1 0.070 (0.622\u22120.823)",
                "sensitivity": "90.6 (80.7 \u221296.5)",
                "specificity": "50.0 (26.0 \u221274.0)",
                "PPV": "86.6",
                "NPV": "59.9",
                "ACC": "81.7"
            },
            "measures": "[level of accuracy, 0.731 \u00b1 0.070 (0.622\u22120.823)]",
            "outcomes": "[0.731 \u00b1 0.070 (0.622\u22120.823)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "152",
                "optimal cutoff value": "1.70",
                "AUC": "0.751 \u00b1 0.067 (0.643\u22120.840)",
                "sensitivity": "89.1 (78.8 \u221295.5)",
                "specificity": "55.6 (30.8 \u221278.5)",
                "PPV": "87.7",
                "NPV": "58.9",
                "ACC": "81.7"
            },
            "measures": "[level of accuracy, 0.751 \u00b1 0.067 (0.643\u22120.840)]",
            "outcomes": "[0.751 \u00b1 0.067 (0.643\u22120.840)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "161",
                "optimal cutoff value": "1.70",
                "AUC": "0.756 \u00b1 0.065 (0.649\u22120.844)",
                "sensitivity": "89.1 (78.8 \u221295.5)",
                "specificity": "55.6 (30.8 \u221278.5)",
                "PPV": "87.7",
                "NPV": "58.9",
                "ACC": "81.7"
            },
            "measures": "[level of accuracy, 0.756 \u00b1 0.065 (0.649\u22120.844)]",
            "outcomes": "[0.756 \u00b1 0.065 (0.649\u22120.844)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "189",
                "optimal cutoff value": "1.75",
                "AUC": "0.770 \u00b1 0.062 (0.664\u22120.856)",
                "sensitivity": "90.6 (80.7 \u221296.5)",
                "specificity": "55.6 (30.8 \u221278.5)",
                "PPV": "87.9",
                "NPV": "62.5",
                "ACC": "82.9"
            },
            "measures": "[level of accuracy, 0.770 \u00b1 0.062 (0.664\u22120.856)]",
            "outcomes": "[0.770 \u00b1 0.062 (0.664\u22120.856)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "214",
                "optimal cutoff value": "1.79",
                "AUC": "0.788 \u00b1 0.059 (0.684\u22120.871)",
                "sensitivity": "92.2 (82.7 \u221297.4)",
                "specificity": "55.6 (30.8 \u221278.5)",
                "PPV": "88.1",
                "NPV": "66.7",
                "ACC": "84.2"
            },
            "measures": "[level of accuracy, 0.788 \u00b1 0.059 (0.684\u22120.871)]",
            "outcomes": "[0.788 \u00b1 0.059 (0.684\u22120.871)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "223",
                "optimal cutoff value": "1.79",
                "AUC": "0.793 \u00b1 0.058 (0.689\u22120.874)",
                "sensitivity": "93.8 (84.8 \u221298.3)",
                "specificity": "55.6 (30.8 \u221278.5)",
                "PPV": "88.3",
                "NPV": "71.6",
                "ACC": "85.4"
            },
            "measures": "[level of accuracy, 0.793 \u00b1 0.058 (0.689\u22120.874)]",
            "outcomes": "[0.793 \u00b1 0.058 (0.689\u22120.874)]"
        },
        {
            "subject": {
                "analysis": "ROC analysis",
                "ROI size": "245",
                "optimal cutoff value": "1.79",
                "AUC": "0.800 \u00b1 0.056 (0.697\u22120.881)",
                "sensitivity": "95.3 (86.9 \u221299.0)",
                "specificity": "55.6 (30.8 \u221278.5)",
                "PPV": "88.4",
                "NPV": "76.9",
                "ACC": "86.6"
            },
            "measures": "[level of accuracy, 0.800 \u00b1 0.056 (0.697\u22120.881)]",
            "outcomes": "[0.800 \u00b1 0.056 (0.697\u22120.881)]"
        },
        {
            "subject": {
                "differential diagnosis": "mass-forming chronic pancreatitis and pancreatic ductal adenocarcinoma",
                "imaging presentation": "similar",
                "treatment strategy": "different"
            },
            "measures": "[clinical significance, high]",
            "outcomes": "[challenging in practice, yes]"
        }
    ],
    "PMC3757392_2": [
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "C595:MUC1",
                "cell line": "Capan-1",
                "ICC": "++",
                "flow": "40",
                "confocal": "++",
                "Do": "170"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[++, 40, ++, 170]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "C595:MUC1",
                "cell line": "Cfpac-1",
                "ICC": "+++",
                "flow": "500",
                "confocal": "+++",
                "Do": "140"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[++, 500, ++, 140]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "C595:MUC1",
                "cell line": "Panc-1",
                "ICC": "+++",
                "flow": "80",
                "confocal": "+++",
                "Do": "160"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[++, 80, ++, 160]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "394:uPA",
                "cell line": "Capan-1",
                "ICC": "++",
                "flow": "88",
                "confocal": "++",
                "Do": "190"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[++, 88, ++, 190]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "394:uPA",
                "cell line": "Cfpac-1",
                "ICC": "+++",
                "flow": "92",
                "confocal": "+++",
                "Do": "130"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[++, 92, ++, 130]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "394:uPA",
                "cell line": "Panc-1",
                "ICC": "+++",
                "flow": "91",
                "confocal": "+++",
                "Do": "170"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[++, 91, ++, 170]"
        },
        {
            "subject": {
                "analysis": "comparison of cell line properties",
                "vector": "2200-2500",
                "cell line": "all cells",
                "ICC": "",
                "flow": "",
                "confocal": "",
                "Do": "2200-2500"
            },
            "measures": "[ICC, flow, confocal, Do]",
            "outcomes": "[]"
        }
    ]
}